Premium
Annovis Bio Inc (ANVS)
NYSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also deve... Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -3.57142857143 | 1.96 | 2.17 | 1.8415 | 1224705 | 1.95671823 | CS |
| 4 | 0.04 | 2.16216216216 | 1.85 | 2.17 | 1.645 | 945159 | 1.82923939 | CS |
| 12 | 0.07 | 3.84615384615 | 1.82 | 2.4705 | 1.645 | 1114157 | 1.95879247 | CS |
| 26 | -1.71 | -47.5 | 3.6 | 3.6147 | 1.5407 | 868015 | 2.08973645 | CS |
| 52 | -0.84 | -30.7692307692 | 2.73 | 5.5 | 1.5407 | 969522 | 2.62986203 | CS |
| 156 | -12.02 | -86.4126527678 | 13.91 | 22.49 | 1.11 | 662485 | 5.54912943 | CS |
| 260 | -107.11 | -98.2660550459 | 109 | 132 | 1.11 | 455714 | 9.43326676 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
